Sutro Biopharma, Inc. (STRO): Price and Financial Metrics


Sutro Biopharma, Inc. (STRO)

Today's Latest Price: $11.40 USD

0.19 (1.69%)

Updated Feb 19 6:55pm

Add STRO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

STRO Stock Summary

  • With a one year PEG ratio of 2.13, Sutro Biopharma Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 10.6% of US stocks.
  • Sutro Biopharma Inc's stock had its IPO on September 27, 2018, making it an older stock than merely 1.21% of US equities in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for STRO comes in at -30.12% -- higher than that of just 10.54% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Sutro Biopharma Inc, a group of peers worth examining would be TBPH, SIMO, IMGN, ONTX, and TROV.
  • Visit STRO's SEC page to see the company's official filings. To visit the company's web site, go to www.sutrobio.com.
STRO Daily Price Range
STRO 52-Week Price Range

STRO Stock Price Chart More Charts


STRO Price/Volume Stats

Current price $11.40 52-week high $12.75
Prev. close $11.21 52-week low $7.69
Day low $11.16 Volume 18,800
Day high $11.73 Avg. volume 78,382
50-day MA $11.28 Dividend yield N/A
200-day MA $10.61 Market Cap 263.23M

Sutro Biopharma, Inc. (STRO) Company Bio


Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was founded in 2003 and is based in South San Francisco, California.


STRO Latest News Stream


Event/TimeNews Detail
Loading, please wait...

STRO Latest Social Stream


Loading social stream, please wait...

View Full STRO Social Stream

STRO Price Returns

1-mo -6.02%
3-mo 8.99%
6-mo 40.39%
1-year 13.66%
3-year N/A
5-year N/A
YTD 3.64%
2019 21.95%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5914 seconds.